Alzheimer disease trials in Bulgaria

In Bulgaria 12 Also abroad 815

12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Where
Pleven, Razgrad, Sofia, Sofiya, Varna
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00
Phase 2/3Taking people
ACP-204 in Adults With Alzheimer's Disease Psychosis
Where
Cherven Bryag, Kirdzhali, Pazardzhik, Pleven, Plovdiv, Sofia, Sofiya
Age
55 years to 95 years
People
1,074 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06159673 · EU 2023-507325-42-00
Phase 3Enrolling by invitation
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Where
Cherven Bryag, Kirdzhali, Pazardzhik, Pleven, Plovdiv, Sofia, Sofiya, Stara Zagora
Age
55 years to 95 years
People
752 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06194799 · EU 2023-507351-29-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Where
Blagoevgrad, Cherven Bryag, Sofia, Stara Zagora, Vratsa
Age
55 years and over
People
370 worldwide
Run by
Intra-Cellular Therapies, Inc.
See details and how to joinNCT06540833
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Where
Lovech, Pleven, Sofia, Sofiya, Stara Zagora
Age
55 years and over
People
320 worldwide
Run by
Intra-Cellular Therapies, Inc.
See details and how to joinNCT06651567 · EU 2024-514680-26-00
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Plovdiv, Ruse, Sofia, Sofiya
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Pleven, Plovdiv, Ruse, Sofia, Sofiya
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Pleven, Razgrad, Sofia, Sofiya, Varna
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Where
Pernik, Ruse, Sofiya
Age
55 years to 90 years
People
300 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00
Phase 2Taking people
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
Where
Blagoevgrad, Cherven Bryag, Sofia, Sofiya, Stara Zagora, Vratsa
Age
18 years and over
People
216 worldwide
Run by
Intra-Cellular Therapies Inc.
See details and how to join2024-513035-25-00 · EU 2024-513035-25-00
Phase 3Taking people
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Where
Cherven Bryag, Pleven, Sofia, Stara Zagora, Vratsa
Age
55 years to 90 years
People
410 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05511363
Phase 2Enrolling by invitation
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Where
Pernik, Sofiya
Age
55 years to 91 years
People
210 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00